PBE-AMF

PBE-AMF

• UNSPSC Description: PBE-AMF is a prodrug that activates H2O2 with anticancer activity. PBE-AMF impedes tumor proliferation by inhibiting DNA synthesis, reducing ATP levels, inducing apoptosis, and arresting the cell cycle. PBE-AMF potently and selectively inhibits the proliferation of MDA-MB-231 cells (IC50=6.4 μM) while sparing non-cancerous MCF-10A cells[1].
• Target Antigen: Apoptosis; DNA/RNA Synthesis; Reactive Oxygen Species
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/pbe-amf.html
• Smiles: O=C(C1=CC(NC(OCC2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=O)=CC4=C1C5=CC=C4)N(CCN(C)C)C5=O
• Molecular Weight: 543.42
• References & Citations: [1]Xueyan Yao, et al. "Amonafide-based H2O2-responsive theranostic prodrugs: Exploring the correlation between H2O2 level and anticancer efficacy." Bioorganic Chemistry (2024): 107560.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported